Sudeep Pharma IPO Details
MAINBOARD
Sudeep Pharma IPO opens for subscription on 21 Nov 2025 and closes on 25 Nov 2025. The IPO will be listed on NSE, BSE with the tentative listing date set for 28 Nov 2025.
Sudeep Pharma IPO price band has been fixed at ₹563 – ₹593 per share.The face value is ₹1 per share with a lot size of 25.
Sudeep Pharma IPO total issue size comprises 1,50,92,750 shares (aggregating up to ₹895.00 Cr.). This includes a fresh issue of 16,02,024 shares (aggregating up to ₹95.00 Cr.). Offer for Sale consists of 1,34,90,726 shares (aggregating up to ₹800.00 Cr.). Pre-issue shareholding stands at 11,13,46,602, which will increase to 11,29,48,626 post-issue.
Sudeep Pharma IPO carries a ₹122 (20.6%) GMP, reflecting investor sentiment.
Sudeep Pharma IPO Lot Size : Retain Minimum is 1 lot (25 shares) amounting to ₹14,825. Retain Maximum is 13 lots (325 shares) amounting to ₹192,725. SHNI Minimum is 14 lots (350 shares) amounting to ₹207,550. SHNI Maximum is 67 lots (1,675 shares) amounting to ₹993,275. BHNI Minimum is 68 lots (1,700 shares) amounting to ₹1,008,100.
The Lead Managers for Sudeep Pharma IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is ICICI Securities Limited, IIFL Capital Services Limited. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Sudeep Pharma Limited RHP.
Sudeep Pharma IPO Details
Sudeep Pharma IPO Subscription
Sudeep Pharma IPO Application Wise Breakup (Approx)
Sudeep Pharma IPO Dates
- 21 Nov 2025Opening dateOPD
- 25 Nov 2025Closing dateCOD
- 26 Nov 2025Allotment Date BOA
- 27 Nov 2025Initiation of RefundsIOR
- 27 Nov 2025Credit of SharesCOS
- 28 Nov 2025Listing dateLID
Sudeep Pharma IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retain Minimum | 1 | 25 | ₹14,825 |
| Retain Maximum | 13 | 325 | ₹192,725 |
| SHNI Minimum | 14 | 350 | ₹207,550 |
| SHNI Maximum | 67 | 1675 | ₹993,275 |
| BHNI Minimum | 68 | 1700 | ₹1,008,100 |
Sudeep Pharma IPO Reservation
Promoter Holding
Sudeep Pharma IPO Valuations
Sudeep Pharma Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Total Income | 130.08 | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 31.27 | 138.69 | 133.15 | 62.32 |
| EBITDA | 48.57 | 199.28 | 187.76 | 98.64 |
| NET Worth | 688.32 | 497.53 | 359.07 | 226.29 |
| Reserves and Surplus | 668.52 | 481.11 | 354.59 | 221.88 |
| Total Borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
| Amount in ₹ Crore | ||||
About Sudeep Pharma IPO
Incorporated in 1989, Sudeep Pharma Limited is a leading manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, serving customers in more than 100 countries.
The company operates six state-of-the-art manufacturing facilities with a combined production capacity of 50,000 MT, offering expertise in key minerals including calcium, iron, magnesium, zinc, potassium, and sodium.
Sudeep Pharma supplies over 200 products to a diverse global customer base across the pharmaceutical, food, and nutrition industries.
The company’s strong R&D capabilities, supported by in-house laboratories and pilot-scale facilities, focus on the development and enhancement of mineral salts and excipients.
Product Portfolio:
- Pharmaceutical, Food and Nutrition Business
- Specialty Ingredients Business
- Triturates
As of December 31, 2024, the company employed 704 permanent staff.
Strength Of Sudeep Pharma IPO
- Market leadership with a diversified product portfolio in a high barrier industry.
- Distinguished global customer base with long-standing relationships with key customers.
- Well-equipped and regulatory compliant Manufacturing Facilities.
- Strong research and development capabilities.
- Experienced Promoters and senior management team.
Risk Of Sudeep Pharma IPO
- We generate a significant portion of our revenues from a limited number of customers and the loss of such customers or a decline in demand from such customers could adversely affect our business, results of operations, financial condition, and cash flows.
- We generated 66.43%, 65.84%, 67.64% and 77.01% of our revenue from operations from our pharmaceutical, food and nutrition segment, in the three months ended June 30, 2025 and Fiscals 2025, 2024 and 2023, respectively. Any adverse developments affecting this segment may adversely affect our business, results of operations, financial condition, and cash flows.
- Our Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers and any manufacturing or quality control problems may subject us to regulatory action, damage our reputation and have an adverse effect on our business and results of operations.
- Three of our four Manufacturing Facilities and one of our two R&D facilities are concentrated in a single region and any adverse developments affecting this region could have an adverse effect on our business, results of operations, financial condition and cash flows.
- Any disruption, slowdown or shutdown in our manufacturing or R&D operations could adversely affect our business, results of operations, financial condition and cash flows.
- We generate a substantial portion of our revenue from operations from our export sales (58.68%, 59.27%, 64.43% and 68.45% of our revenue from operations for the three months ended June 30, 2025 and Fiscals 2025, 2024 and 2023, respectively) and any adverse developments in such regions, including the imposition of tariffs or other anti-sourcing legislation, could adversely affect our business, results of operations, financial condition and cash flows.
- If we are unable to introduce new products in a timely manner or if the products we commercialize do not perform as expected, our business, results of operations, financial condition and cash flows may be adversely affected.
- We have recently undertaken the NSS Acquisition and may undertake similar acquisitions, investments, joint ventures or other strategic alliances in the future, which if unsuccessful, may adversely affect our business, results of operations and financial condition.
- Any delay, interruption or reduction in the supply of raw materials and equipment to manufacture our products may adversely affect our business, results of operations, financial condition and cash flows.
- Our past performance may not be indicative of our future growth. We may not be successful in implementing and managing our expansion and growth strategy effectively. Further, we intend to diversify into different businesses beyond the pharmaceutical sphere, and failure to successfully implement such business ventures can negatively impact our results of operations and financial condition.
Objectives Sudeep Pharma IPO
1. Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility.
2. General corporate purposes.
Company Contact Details
Sudeep Pharma Limited
129/1/A, GIDC Estate, Nandesari, Vadodara – 391340, Gujarat, India
Phone: +91 265 284 0656
Email: cs.sudeep@sudeepgroup.com
Website: https://www.sudeeppharma.com/